New cancer drug trial tests hope for Tough-to-Treat tumors
NCT ID NCT05223231
Summary
This early-stage study tested a new drug called LBL-019, given alone or with an existing immunotherapy, in people with advanced cancers that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the treatment showed any early signs of helping control the cancer. It involved a small group of adults whose other treatment options were limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350000, China
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410006, China
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
-
The first affiliated hospital with Nanjing medical university
Nanjing, Jiangsu, 210000, China
-
Union hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.